EGFR and non-small cell lung carcinoma: This is in contradiction to the data from the INTEREST study [14], which nonetheless compared gefitinib with docetaxel regardless of EGFR mutation information and to the data from the Tarceva In Treatment of Advanced NSCLC (TITAN) study [15], which compared erlotinib with chemotherapy in EGFR wild-type patients.